Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antithymocyte Globulin in New Onset Type 1 Diabetes
NCT00515099Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2007
- Primary completion
- Jun 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Antithymocyte globulin with Placebo (2 arms). Primary endpoint: 2-Hour C-peptide Area Under the Curve at Month 12. Started Aug 2007; status: terminated.
02
Drugs
antithymocyte globulin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00515099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515099.